Lumos Pharma(LUMO) - 2019 Q2 - Quarterly Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended June 30, 2019. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 001-35342 NEWLINK GENETICS CORPORATION (Exact name of Registrant as specified in Its Charter) (State or other jurisdiction o ...